Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Susanna Banerjee explained that elevated creatine phosphokinase from avutometinib and defactinib represents an asymptomatic biochemical rise rather than cardiac damage or rhabdomyolysis. Trialists initially set overly strict dose interruption guidelines before recognizing patients had no corresponding muscle symptoms.

Related Insights

Peripheral edema from MET inhibitors like capmatinib or tepotinib is cumulative and unavoidable over long-term treatment. Dr. Liu notes that diuretics merely elevate creatinine and compression stockings simply displace fluid. Instead of continuing until disease progression, clinicians should reduce doses and implement temporary treatment breaks until swelling recedes to an acceptable baseline, resuming therapy before tumor progression occurs.

While hyperphosphatemia is an expected on-target effect of the FGFR inhibitor erdafitinib, clinicians find that side effects like stomatitis, diarrhea, dry mouth, and fatigue more frequently lead to dose reductions or discontinuation. Proactive management of these seemingly secondary toxicities is crucial for keeping patients on this effective therapy.

An observed signal for cardiac dysfunction in the Lenvatinib-Belzutifan arm of a recent trial is causing concern among clinicians. The lack of detailed characterization for this toxicity makes it a significant point of discussion and an area requiring more data before the regimen's safety profile is fully understood.

While trametinib carries a ~6% risk of congestive heart failure, this specific toxicity has not been observed with the avutametinib/defactinib combination. This distinct safety profile makes the doublet a potentially safer option, especially for patients with cardiac risk or who failed trametinib due to heart issues.

Despite initial concerns that combining pertuzumab and tucatinib would exacerbate severe diarrhea, grade 3 diarrhea increased by only 2% over placebo. Rather than gastrointestinal issues, elevated liver function tests occurred in approximately 25% of patients and served as the leading driver of dose holds, reductions, and treatment discontinuations.

Creatine supplementation is safe for kidneys. However, its natural breakdown product is creatinine, the marker used to *estimate* kidney function. This elevates creatinine in the blood, causing a lower calculated filtration rate (eGFR) that doctors can misinterpret as kidney damage. It's a measurement artifact, not a physiological problem.

A key clinical strategy for managing the TKI Zongertinib is proactive liver function monitoring. Checking AST/ALT every two weeks for the first three months allows clinicians to intervene with dose holds at the first sign of mild elevations, thereby preventing severe toxicity that would mandate a dose reduction.

The doublet's unique dosing schedule (twice-weekly pills for three weeks, then one week off) is crucial for its long-term success. This "recovery week" per cycle is thought to reduce cumulative toxicity, allowing patients to stay on this highly effective therapy for extended periods.

CPK elevation is a frequent lab finding with avutametinib but is almost always asymptomatic and doesn't cause clinical muscle weakness. This understanding has led to less stringent criteria for drug discontinuation, allowing more patients to remain on effective therapy despite the biomarker change.

Clinicians should not halt abemaciclib for a mild rise in creatinine, as it's often a spurious lab finding due to altered tubular secretion, not renal injury. Ordering a cystatin C test can confirm normal kidney function, allowing patients to safely continue treatment.